Return-Path: <linux-kernel-owner+willy=40w.ods.org-S262548AbVF2LHW@vger.kernel.org>
Received: (majordomo@vger.kernel.org) by vger.kernel.org via listexpand
	id S262548AbVF2LHW (ORCPT <rfc822;willy@w.ods.org>);
	Wed, 29 Jun 2005 07:07:22 -0400
Received: (majordomo@vger.kernel.org) by vger.kernel.org id S262525AbVF2LGg
	(ORCPT <rfc822;linux-kernel-outgoing>);
	Wed, 29 Jun 2005 07:06:36 -0400
Received: from 71-36-17-141.bois.qwest.net ([71.36.17.141]:23564 "HELO
	71-36-17-141.bois.qwest.net") by vger.kernel.org with SMTP
	id S262538AbVF2LEq (ORCPT <rfc822;linux-kernel@vger.kernel.org>);
	Wed, 29 Jun 2005 07:04:46 -0400
Mime-Version: 1.0 (Intermedia news script)
Content-Transfer-Encoding: 7bit
Message-Id: <10956238148.39520129639@71-36-17-141.bois.qwest.net>
Content-Type: text/plain; charset=US-ASCII
To: linux-kernel@vger.kernel.org
From: Ronald <americium@chrismarino.com>
Subject: Is Momentum Building for This Small-Cap?
Date: Wed, 29 Jun 2005 05:04:53 -0600
X-Mailer: Intermedia news script
Sender: linux-kernel-owner@vger.kernel.org
X-Mailing-List: linux-kernel@vger.kernel.org

TUESDAY 06/28/05 Its moving already..

EXCITING ISSUE PGCN.OB GET IN NOW!!!

(OTC Ti.cker: PGCN.OB)

Current Price $1.75
5-Day Target: $6
10-Day Target: $11
3-Month Target: $25-28 or Higher

PRESS RELEASE

Pingchuan Signed Market Research Consignment Agreement With Moscow Sing Sing
Co. Ltd

Thursday June 23, 10:31 am ET


HARBIN, China, June 23 /Xinhua-PRNewswire/ -- Pingchuan Pharmaceutical Inc.
(OTC Bulletin Board: PGCN.OB - News; "PINGCHUAN") announced today that
PINGCHUAN signed a market research consignment agreement with Moscow Sing
Sing Co. Ltd ("SING SING").

ADVERTISEMENT

According to the agreement, SING SING authorized PINGCHUAN as its exclusive
partner to conduct market researches for business projects in P. R. China
(exclude Hong Kong, Macao and Taiwan). PINGCHUAN promises to accomplish
commercial market researches and deliver business plans for SING SING within
the valid period of the agreement. The co-operation with SING SING, will
bring in revenue of USD 200,000 for PINGCHUAN.

HERE IS ANOTHER GOOD REASON TO LOOK AT PGCN.OB

Pingchuan Pharmaceutical Inc. ("PINGCHUAN") is a modernized
pharmaceutical manufacturer with first-class medical R&D ability, pioneered
medicine products, and well-established marketing network. Since its
establishment, PINGCHUAN has focused its businesses on diabetes medicine and
its medical products. The products of PINGCHUAN include health care
products, varieties of medicine, as well as medical apparatus. Kang Da
Glycosuria Capsule is a successful product of PINGCHUAN for treating
diabetes, which was first developed in 1998 and introduced to the market in
2001. PINGCHUAN has well-established marketing network and sale branches,
which include about 180,000 retail pharmacies/drugstores across China,
agency network in major cities like Beijing, Shanghai, Guangzhou, and Xi'an,
special counter sale at drug chain stores in key regions, residence
community clinic sale and promotion, as well as internet marketing through
the company's website. The marketing network of PINGCHUAN covers more than
50% districts of China and exports to US, Japan, Russia, and south-eastern
Asia.


Sick of hedge funds and flippers getting all the great new issues? Most
s.tock brokers give out their new issues to their largest commission paying
clients---and if you trade through an online broker or discount
broker---good luck ever getting 1 share of a new issue.

WELL ALL THAT IS CHANGING -- THIS IS AN ONLINE INTERNET IPO. IF YOU ARE
RECEIVING THIS EMAIL, YOU ARE AMONG THE FIRST PUBLIC INVESTORS TO KNOW ABOUT
PGCN.OB !!!!



Remember the gains from our recent  Strong B.uy  recommendations...

It is only a matter of time before it is released out into the investment
community and they take it to the moon..




